Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Development of Chiral Carbon Dots for Boosting Cancer Immunotherapy

Project description

Biocompatible nanomedicines for cancer

Nanoparticles are emerging as a powerful tool in cancer immunotherapy, offering precise delivery and enhanced efficacy of treatments. These tiny particles can be engineered to carry various therapeutic agents directly to cancer cells, minimising damage to healthy tissues. Funded by the Marie Skłodowska-Curie Actions programme, the ChiralBoost project focuses on carbon dots (CDs) as agents for immunotherapy, given their good biocompatibility. Researchers will functionalise CDs with tumour antigens and immune adjuvants and study their effect on primary immune cell maturation. Project results on CDs could expand their utilisation beyond cancer treatment for broader biomedical applications.

Objective

Cancer immunotherapy is considered an effective cancer treatment strategy. However, there are still some obstacles, including the unresponsive state of the immune system to tumor antigen stimulation. In the last years, researchers have found that nanomaterials can modulate the immune system. Among many excellent nanomaterials, carbon-based nanomaterials stand out due to their good biocompatibility. Compared to the rich research on carbon nanotubes and graphene oxide, the research on carbon dots (CDs) in immunotherapy is still in its infancy. In ChiralBoost, we intend to explore the application of chiral carbon dots (Ch-CDs) in cancer immunotherapy. Ch-CDs will be synthesized by hydrothermal and microwave methods using protected L/D-tyrosine and L/D-tryptophan as precursors. Then, a tumor antigen model ovalbumin peptide and the immune adjuvant monophosphoryl lipid A will be grafted onto the Ch-CDs through post-functionalization. Next, the interaction and the immune response of the Ch-CDs on primary immune cells in vitro and in vivo, such as the ability to accelerate dendritic cell maturation and the ability to stimulate cytokine production will be explored. The generated results will open the way to explore the potential of Ch-CDs in cancer immunotherapy The conduct of this project is not only expected to the development of Ch-CDs-based anticancer nanomedicines but will also pave the way for biomedical applications of chiral nanomaterials in other potential clinical applications. The assembled research team is totally capable of achieving the ambitious objectives of the proposed project. The researcher, Dr. Hu, is a multidisciplinary researcher specializing in diverse carbon nanomaterials. The main supervisor (Dr. Alberto Bianco, Institute of Molecular and Cell Biology, CNRS) is among the pioneers of biomedical carbon-nanomaterials research, and the secondment co-supervisor (Prof. Sara Bals, University of Antwerp) is a renowned expert on microscopic techniques.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2023-PF-01

See all projects funded under this call

Coordinator

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Net EU contribution
€ 208 476,88
Address
RUE MICHEL ANGE 3
75794 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
No data

Partners (1)